Armata Pharmaceuticals's three largest insider shareholders as of September 09, 2026 are Inc. Innoviva, (Director, 16.37Mn shares), Deborah Birx (Chief Executive Officer, 198.42K shares), Richard Rychlik (Corporate Controller And Pfo, 10.00K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Inc. Innoviva, | Director, TenPercentOwner | 0 | 16,365,969 | 16,365,969 | 98.7% | 01 Apr, 2022 |
| 2 | Deborah Birx | Chief Executive Officer | 198,417 | 0 | 198,417 | 1.2% | 14 Jul, 2026 |
| 3 | Richard Rychlik | Corporate Controller And Pfo | 10,000 | 0 | 10,000 | 0.1% | 18 Mar, 2024 |
| 4 | Pierre Kyme | Chief Business Officer | 9,461 | 0 | 9,461 | 0.1% | 17 Mar, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 10 Jul, 2026 | Deborah Birx | Chief Executive Officer | Disposed F | 14,041 | $4.26 | $59.81K | 198,417 | Direct |
| 24 Apr, 2026 | Daniel B. Gilmer | Director | Acquired A | 51,280 | $0.00 | $0 | 51,280 | Direct |
| 14 Mar, 2026 | Pierre Kyme | Chief Business Officer | Disposed F | 1,030 | $10.54 | $10.86K | 9,461 | Direct |
| 14 Mar, 2026 | Pierre Kyme | Chief Business Officer | Disposed F | 1,030 | $10.54 | $10.86K | 9,461 | Direct |
| 14 Mar, 2026 | Deborah Birx | Chief Executive Officer | Disposed F | 4,919 | $10.54 | $51.85K | 212,458 | Direct |
| 14 Mar, 2026 | Pierre Kyme | Chief Business Officer | Disposed F | 1,030 | $10.54 | $10.86K | 9,461 | Direct |
| 14 Mar, 2026 | Pierre Kyme | Chief Business Officer | Disposed F | 1,030 | $10.54 | $10.86K | 9,461 | Direct |
| 09 Mar, 2026 | Sarah J. Schlesinger | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Joseph M Patti | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Robin Kramer | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | David Duane House | Svp, Finance, And Pfo | Acquired A | 109,885 | $0.00 | $0 | 109,885 | Direct |
| 09 Mar, 2026 | Robin Kramer | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Pierre Kyme | Chief Business Officer | Acquired A | 183,142 | $0.00 | $0 | 183,142 | Direct |
| 09 Mar, 2026 | Kostas D Odysseas | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Todd C. Peterson | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Todd C. Peterson | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | David Duane House | Svp, Finance, And Pfo | Acquired A | 109,885 | $0.00 | $0 | 109,885 | Direct |
| 09 Mar, 2026 | Joseph M Patti | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Robin Kramer | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |
| 09 Mar, 2026 | Kostas D Odysseas | Director | Acquired A | 25,640 | $0.00 | $0 | 25,640 | Direct |